Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 August 2004, Vol. 104, No. 3, pp. 607-618.
Prepublished online as a Blood First Edition Paper on April 15, 2004; DOI 10.1182/blood-2004-01-0037.

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-01-0037v1
104/3/607    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hideshima, T.
Right arrow Articles by Anderson, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hideshima, T.
Right arrow Articles by Anderson, K. C.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Right arrow Cell Cycle
Right arrow Cell Adhesion and Motility
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrow Gene Expression
Right arrow Reviews in Translational Hematology
Right arrow Free Research Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW IN TRANSLATIONAL HEMATOLOGY

Advances in biology of multiple myeloma: clinical applications

Teru Hideshima, P. Leif Bergsagel, W. Michael Kuehl, and Kenneth C. Anderson

From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Weill Medical College of Cornell University, New York, NY; and the Genetics Branch, National Cancer Institute, Bethesda, MD.

Abstract

There appear to be 2 pathways involved in the early pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple myeloma (MM) tumors. Nearly half of these tumors are nonhyperdiploid and mostly have immunoglobulin H (IgH) translocations that involve 5 recurrent chromosomal loci, including 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (fibroblast growth factor receptor 3 [FGFR3] and multiple myeloma SET domain [MMSET]), 16q23 (c-maf), and 20q11 (mafB). The remaining tumors are hyperdiploid and contain multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, but infrequently have IgH translocations involving the 5 recurrent loci. Dysregulated expression of cyclin D1, D2, or D3 appears to occur as an early event in virtually all of these tumors. This may render the cells more susceptible to proliferative stimuli, resulting in selective expansion as a result of interaction with bone marrow stromal cells that produce interleukin-6 (IL-6) and other cytokines. There are 5 proposed tumor groups, defined by IgH translocations and/or cyclin D expression, that appear to have differences in biologic properties, including interaction with stromal cells, prognosis, and response to specific therapies. Delineation of the mechanisms mediating MM cell proliferation, survival, and migration in the bone marrow (BM) microenvironment may both enhance understanding of pathogenesis and provide the framework for identification and validation of novel molecular targets.

Introduction

On January 1, 2000, there were estimated to be 47 000 patients with multiple myeloma (MM) in the United States, reflecting a yearly incidence of nearly 14 000 and a median survival of about 3 years.1 Currently it remains an incurable malignancy that often is preceded by an exceptionally common (3.4% of the population over the age of 502) premalignant tumor, monoclonal gammopathy of undetermined significance (MGUS). Monoclonal gammopathies are usually asymptomatic, but they may sometimes cause primary amyloidosis as a result of pathologic, and ultimately lethal, deposits of monoclonal immunoglobulin (Ig) in critical tissues.3 Although MGUS is stable, it stochastically progresses to frankly malignant MM at a rate of 0.6% to 3% per year, depending on the level of monoclonal Ig.4 For both MGUS and MM, the incidence is markedly age dependent, about 2-fold higher in American blacks than whites, and significantly higher in males.5 Although for many years the incidence of MM appeared to be increasing, since 1992 the incidence appears to have become stable. The roles of genetic background and environment are poorly defined, although there may be clustering within families.6

MM is a plasmablast/plasma cell tumor characterized by frequent Ig translocations

Germinal center B cells uniquely modify the DNA of Ig genes through sequential rounds of somatic hypermutation and antigen selection, and also by IgH switch recombination. Postgerminal center B cells can generate plasmablasts (PBs) that have successfully completed somatic hypermutation and IgH switching before migrating to the bone marrow (BM), where stromal cells enable terminal differentiation into long-lived plasma cells (PCs).7,8 MGUS and MM are characterized by the accumulation of transformed PBs/PCs at multiple sites in the BM. Importantly, although MM is more proliferative than MGUS, both tumors have an extremely low rate of proliferation, typically with less than 1% of cells synthesizing DNA until late stages of MM. The combination of karyotypic complexity, an inability to efficiently perform conventional cytogenetics on low proliferative tumors, and the telomeric location of some translocation partners delayed the identification of Ig translocations in MGUS and MM. An important initial step in solving this problem was the identification and cloning of IgH switch region translocation breakpoints in human myeloma cell lines (HMCLs).9 Interphase fluorescence in situ hybridization (FISH) using probes flanking the cloned breakpoints identifies karyotypic abnormalities even in nondividing cells and enabled the analysis of primary MGUS and MM tumors.10,11 Several studies have shown that a majority of MM tumors have an IgH translocation that nonrandomly involves one of many potential chromosomal partners.9,12-14 The prevalence of IgH translocations varies with the stage of disease: 46% to 48% in MGUS or smoldering MM (SMM), 55% to 73% in intramedullary MM, 85% in primary plasma cell leukemia, and more than 90% in HMCLs.8,14

Recurrent chromosomal partners for Ig translocations

There are 5 well-defined recurrent chromosomal partners (oncogenes) that are involved in IgH translocations in MGUS and MM: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (fibroblast growth factor receptor 3 [FGFR3] and multiple myeloma SET domain [MMSET]), 16q23 (c-maf), and 20q11 (mafB).9 Together the combined prevalence of these 5 IgH translocation partners is about 40%, with approximately 15% 11q13, 3% 6p21, 15% 4p16, 5% 16q23, and 2% 20q11.8,12,15-18 The t(4;14) translocation is unusual in that it appears to dysregulate 2 potential oncogenes, MMSET on der(4) and FGFR3 on der(14), although FGFR3 on der(14) is lost or not expressed in about 20% of MM tumors that have a t(4;14) translocation.19-23 The apparently lower incidence of 4p16 and/or 16q23 in MGUS/SMM compared with MM may be due to these translocations resulting in de novo MM without preceding MGUS, or a more rapid progression of MGUS to MM, a hypothesis supported by the fact that patients with translocations involving 4p16 or 16q23 have an extremely poor prognosis.12,13,22,24

Primary versus secondary translocations in MM

Primary translocations occur as early and perhaps initiating events during tumor pathogenesis, whereas secondary translocations occur as progression events. Most translocations involving the 5 recurrent translocation partners appear to be primary translocations that occurred from errors in IgH switch recombination during B-cell development in germinal centers. In contrast, translocations of c-myc appear to be very late secondary events that do not involve B-cell–specific recombination mechanisms, are often complex, and sometimes do not involve Ig loci. By FISH analysis, rearrangements of c-myc are reported in only 15% of MM tumors (with frequent heterogeneity within a tumor), but in nearly 40% of advanced MM tumors and 90% of HMCLs.25,26 Regarding the approximately 20% of IgH translocations not involving the 6 recurrent partners, little is known about the multitude of partners and oncogenes, the mechanisms that mediate these translocations, or the time(s) at which these translocations occur.

Dysregulation of cyclin D1, D2, or D3: a unifying oncogenic event in MM

MGUS and MM appear closer to normal, nonproliferating PCs than to normal, but highly proliferating PBs, for which 30% or more of the cells can be in S phase. It is surprising therefore that analysis by Bergsagel and Kuehl27 of combined gene expression profiling data published from 2 laboratories28,29 shows that the expression level of cyclin D1, cyclin D2, or cyclin D3 mRNA in MM and MGUS is distinctly higher than in normal PCs, comparable with the levels of cyclin D2 mRNA expressed in normal proliferating PBs (Figure 1). Normal hematopoietic cells, including normal B lymphocytes, PCs, and PBs, express cyclin D2 and/or D3, but little or no cyclin D1.30 Given the lack of cyclin D1 expression in normal lymphocytes, the occurrence of Ig translocations that dysregulate cyclin D1 or cyclin D3 in about 20% of MM tumors, the expression of cyclin D1 in nearly 40% of tumors lacking a t(11;14) translocation, and the increased expression levels of cyclin D2 in most remaining tumors, it seems apparent that almost all MM tumors dysregulate at least one of the cyclin D genes.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 1.. Cyclin D expression in normal and malignant plasma cells. The raw scores for each of the 3 D-cyclins (D1, green bars; D2, red bars; D3, blue bars) from the Affymetrix HuFL dataset published by Tarte et al28 and Zhan et al29 are plotted one above the other. The samples are divided into 9 groups, and arranged by the level of expression of the predominant cyclin D within each group. The samples are CD138+ selected cells from 6 peripheral blood generated plasmablasts and 1 reactive plasmacytosis (PPC), 31 bone marrow PCs (BMPC) from healthy volunteers, and 78 samples from patients with newly diagnosed MM and 3 with plasma cell leukemia. Among these there are 2 with high CCND3 (6p21) and 15 with high CCND1 (11q13) (TC1); 25 with lower levels of CCND1 without t(11;14) (TC2); 4 with lower levels of D1 and elevated CCND2 (D1 + D2), 17 remaining patients with elevated CCND2 (other), and 2 patients without an elevated cyclin D (TC3); 9 with elevated FGFR3 (4p16) (TC4); and 7 with elevated CX3CR1 and {beta}7 integrin, a marker of maf dysregulation (maf, 16q23 and 20q11) (TC5).

 

A model for the molecular pathogenesis of multiple myeloma

Based on the results summarized, a model for the molecular pathogenesis of MM has been proposed.8 Chromosome content appears to identify 2 different—but perhaps overlapping— pathways of pathogenesis: nonhyperdiploid tumors with a very high incidence of IgH translocations involving the 5 recurrent partners and a relatively high incidence of chromosome 13/13q14 loss; and hyperdiploid tumors associated with multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, but a low incidence of both chromosome 13/13q14 loss and IgH translocations involving the 5 recurrent partners31-33 (Figure 2). In about half of tumors, a primary chromosome translocation results in the dysregulated expression of an oncogene. This may lead directly (11q13-cyclin D1 and 6p21-cyclin D3) or indirectly (4p16, 16q23, other cyclin D2) to cyclin D dysregulation. Alternatively, the remaining tumors are mostly hyperdiploid, and cyclin D1 (or less often cyclin D2) usually is dysregulated by an undefined mechanism.27 The dysregulation of 1 of 3 cyclin D genes may render the cells more susceptible to proliferative stimuli, resulting in selective expansion as a result of interaction with bone marrow stromal cells (BMSCs) that produce interleukin-6 (IL-6) and other cytokines. Karyotypic abnormalities, most notably IgH translocations, trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, and monosomy of chromosome 13 or 13q14 deletion, often are present in premalignant MGUS, the earliest identified stage of tumorigenesis.12,14 Even though dysregulation of a cyclin D gene appears to be a nearly universal event in early pathogenesis, there is evidence that the retinoblastoma (Rb) pathway is further disrupted by p16INK4a methylation and inactivation in a substantial fraction of MGUS and MM tumors.34,35 Tumor progression is associated with secondary chromosome translocations, of which c-myc provides a paradigm.8,26 Mutually exclusive activating mutations of K- or N-Ras (or FGFR3 when there is a t(4;14) translocation) are rare or absent in MGUS, whereas Ras mutations are present in 30% to 40% of early MM, and FGFR3 mutations occur more frequently in advanced MM.21,36-38 Mutations and/or monoallelic deletion of p53 occur frequently but only late in the course of the disease.39 Further disruption of the Rb pathway by inactivation of Rb or p18INK4c can also occur at a low frequency, most likely as a late progression event.40,41 The frequency and timing of other events, such as inactivation of phosphatase and tensin homolog (PTEN), remain to be determined.42,43



View larger version (32K):
[in this window]
[in a new window]
  		Figure 2.. Two pathways for progression to plasma cell neoplasia. Defined stages of pathogenesis are depicted, with shaded triangles indicating the possible timing and frequency of known oncogenic events. The earliest changes include 2 partially overlapping pathways, indicated by primary IgH translocations (tx) and multiple trisomies. Deletion 13 (most often in nonhyperdiploid tumors) and p16 methylation might be included among the earliest changes, but might sometimes be involved in progression. Activating mutations of N- and K-RAS appear to mark, if not cause, the MGUS to MM transition in some tumors, but can also occur as later progression events. Late oncogenic changes include inactivation of p18 and p53, and also translocations that dysregulate c-myc. Inactivation of Rb, PTEN, and secondary translocations not involving c-myc are not depicted.

 

Proposal for 5 MM subtypes defined by translocations and cyclin D expression (TC classification)

In addition to determining the expression level of cyclin D1, D2, and D3, gene expression profiling can effectively identify MM tumors that overexpress the oncogenes dysregulated by the 5 recurrent IgH translocations: 11q13 (cyclin D1); 6p21 (cyclin D3); 4p16 (MMSET and usually FGFR3); 16q23 (c-maf); and 20q11 (mafB).27,29 We propose 5 translocation and cyclin D (TC) groups (Table 1) that can be distinguished based on the 5 recurrent Ig translocations and cyclin D expression: TC1 tumors (18%) express high levels of either cyclin D1 or cyclin D3 as a result of an Ig translocation; TC2 tumors (37%) ectopically express low to moderate levels of cyclin D1 despite the absence of a t(11;14) translocation; TC3 tumors (22%) are a mixture of tumors that do not fall into one of the other groups, with most expressing cyclin D2, but a few also expressing low levels of cyclin D1 or cyclin D3; TC4 tumors (16%) express high levels of cyclin D2, and also MMSET (and in most cases FGFR3) as a result of a t(4;14) translocation; and TC5 tumors (7%) express the highest levels of cyclin D2, and also high levels of either c-maf or mafB, consistent with evidence that both maf transcription factors up-regulate the expression of cyclin D2.44


View this table:
[in this window]
[in a new window]
  		Table 1.. Translocation and cyclin D (TC) molecular classification of multiple myeloma

 

The TC molecular classification predicts prognosis and response to therapies

In addition to tumor mass and secondary features that represent a host response to MM (anemia, thrombocytopenia, bone disease, immunodeficiency, etc), intrinsic properties of the tumor cell are also informative in predicting prognosis and response to existing therapies. For example, it has been well documented that an unfavorable outcome is associated with each of the following: increased plasma cell labeling index, the generation of tumor cells with an abnormal karyotype (perhaps a surrogate for increased proliferation), hypodiploidy compared with hyperdiploidy, monosomy of chromosome 13/13q, monosomy of chromosome 17/deletion of p53, and lack of cyclin D1 expression.7,13,31-33,45,46 It also has been reported and independently confirmed that activating mutations of K-Ras (but not N-Ras) represent an adverse prognostic factor.37,38 More recently, it has become clear that specific IgH translocations also have a profound prognostic significance13,24 (Table 1). In particular, patients with tumors that have a t(4;14) translocation (TC4) have a substantially shortened survival either with standard or high-dose therapy (median overall survival [OS], 26 months and 33 months, respectively), and patients with a t(14;16) (TC5) have a similarly poor if not worse prognosis (median OS, 16 months with conventional therapy). By contrast, patients with tumors that have a t(11;14) translocation (TC1) appear to have a marginally better survival following conventional chemotherapy (median OS, 50 months), but apparently a remarkably better survival following intense therapy (predicted 88% OS at 80 months). These results suggest that the TC classification, which appears to be based on the earliest events in pathogenesis, may be a clinically useful way to classify patients into groups that have distinct subtypes of MM (and MGUS) tumors.13,47-49 The TC classification identifies clinically important molecular subtypes of MM with different prognoses and with unique responses to different treatments (eg, high dose therapy [HDT] and TC1, microenvironment-directed therapy and TC2, FGFR3 inhibitor and TC4, maf dominant-negative and TC5).

Identification of novel therapeutic strategies targeting genetic abnormalities

The critical role of cyclin D dysregulation in the pathogenesis of MM highlights the importance of the cyclin D/Rb pathway and suggests that there may be a therapeutic window in targeting this pathway50 for all molecular subtypes of MM (Figure 3). For example, epigenetic silencing of cyclin-dependent kinase (CDK) inhibitor mRNA expression might be reversed by histone deacetylase (HDAC) inhibitors (suberoylanilide hydroxamic acid [SAHA], depsipeptide) or inhibitors of DNA methyl transferase (5 aza-2'deoxy-cytidine).51 To target cyclin D, per se, there are a number of possible strategies including modulation of mRNA translation (eg, desferroxamine, eicosapentaenoic acid),52,53 posttranslational modifications (ubiquitination and proteasomal degradation),54,55 enzyme function (selective CDK kinase inhibitors),50,56 and perhaps even inhibition of expression of cyclin D mRNA (the TC2 group may be particularly dependent on interaction with BM stromal cells for the ectopic expression of cyclin D1). Additional specificity may be achieved by targeting the genes directly dysregulated by translocations. This seems to be especially true in the case of the t(4;14) where 2 enzymes are overexpressed: FGFR3, a tyrosine kinase receptor, and MMSET, which has homology to histone methyltransferases. As a surface receptor, FGFR3 may be targeted by monoclonal antibodies, and as a tyrosine kinase, by selective tyrosine kinase inhibitors. Preclinical studies have validated FGFR3 as a therapeutic target in t(4;14) MM,57 inhibitors of histone methyltransferases are being developed, and studies are under way to validate MMSET as a target in t(4;14) MM.



View larger version (37K):
[in this window]
[in a new window]
  		Figure 3.. Critical role for cyclin D/Rb pathway in multiple myeloma. The 5 TC molecular subtypes of myeloma are characterized by either direct (solid arrow) or indirect (dashed arrow) dysregulation of a D cyclin. Cyclin D together with CDK4 and 6 is involved in G1-S cell cycle progression by phosphorylating and inactivating Rb. This reaction is inhibited by the CDK inhibitors INK4a-d. In addition to cyclin D, other members that are targeted by genetic mutation in MM are highlighted (p16 by methylation, p18 by small homozygous deletions, and Rb by monoallelelic deletion).

 

Critical but variable role for the bone marrow (BM) microenvironment

Similar to their normal BM plasma cell (BMPC) counterpart, MGUS and MM tumors are dependent on mutual interactions with cells and extracellular components of the BM for survival and growth. Exceptions to this include primary plasma cell leukemia (PCL) and terminal phases of MM, which sometimes extend to extramedullary sites. Significantly, virtually all HMCLs are derived from PCL or extramedullary tumor. Although not yet well understood, there is increasing evidence that some of the earliest oncogenic events differentially affect the interaction of tumor cells with BM components. First, tumors in the TC1 and TC2 groups are more strongly associated with lytic bone lesions than tumors in the TC4 and TC5 groups (P.L.B., unpublished observations, January 2004).58 Second, the maf transcription factor–stimulated expression of {beta}7 integrin and other surface receptors or cytokines seems likely to influence the interactions of the TC5 tumor group in the BM.44 Third, in contrast to tumors in the other TC groups, TC2 tumors (hyperdiploid with multiple trisomies and cyclin D1 expression without a t(11;14)) are greatly underrepresented or absent in primary PCL59 and HMCLs.27 Thus TC2 tumors may be uniquely dependent on the BM environment, with the possibility that the ectopic/increased expression of cyclin D1 is dependent on the BM microenvironment. For example, IL-6 secreted by BMSCs triggers phosphorylation of Akt and downstream glycogen synthase kinase 3{beta} (GSK-3{beta}).60 GSK-3{beta} in turn induces phosphorylation of cyclin D1 followed by degradation through the ubiquitin-proteasome pathway, thereby promoting the transition from G1 to S phase.61 Tumor necrosis factor {alpha} (TNF{alpha}) in the BM milieu activates nuclear factor {kappa}B (NF-{kappa}B), thereby modulating expression of adhesion molecules on both MM cells and BMSCs, as well as inducing IL-6 transcription and secretion in BMSCs. Activated NF-{kappa}B also binds to the promoter of cyclin D1, thereby regulating its expression.62,63

Growth and survival of MM in the bone marrow (BM) milieu

MM cells home to the BM and adhere to extracellular matrix (ECM) proteins and to BM stromal cells (BMSCs), which not only localizes tumor cells in the BM milieu but also has important functional sequelae.64 Specifically, adhesion of MM cells to ECM proteins confers cell adhesion–mediated drug resistance (CAM-DR),65-67 and binding of MM cells to BMSCs triggers transcription and secretion of cytokines (ie, IL-6, insulin-like growth factor 1 [IGF-1], or vascular endothelial growth factor [VEGF]) from BMSCs, which not only promotes growth, survival, and migration of MM cells but also further confers resistance to conventional chemotherapy.60,68-72 Delineation of mechanisms mediating MM cell growth, survival, and drug resistance in the BM milieu provides the framework to develop and validate novel anti-MM agents to overcome drug resistance and improve patient outcome.73

Role of adhesion molecules

Adhesion molecules mediate both homotypic and heterotypic adhesion of MM cells to either ECM proteins or BMSCs.64 Adhesion molecules CD44, very late antigen 4 (VLA-4), VLA-5, leukocyte function-associated antigen-1 (LFA-1, CD11a), CD56 (neural cell adhesion molecule), CD54 (intercellular adhesion molecule-1 [ICAM-1]), syndecan-1 (CD138), and MPC-1 mediate homing of MM cells to the BM. Subsequently, tumor cells binds to ECM proteins (ie, via syndecan-1 and VLA-4 on MM cells to type I collagen and fibronectin, respectively) and to BMSCs (ie, via VLA-4 on MM cells to vascular cell adhesion molecule 1 [VCAM-1, CD106] on BMSCs; Figure 4). Binding not only localizes tumor cells in the BM microenvironment, but also has important functional and clinical sequelae. Syndecan-1 regulates tumor cell growth and survival, and elevated serum levels correlate with increased tumor cell mass, decreased metalloproteinase-9 activity, and poor prognosis.74,75 Furthermore, adhesion of MM cells via syndecan-1 to collagen induces matrix metalloproteinase-1, thereby promoting bone resorption and tumor invasion. Importantly, binding via VLA-4 on MM cells to the ECM protein fibronectin triggers up-regulation of p27Kip1 and other genetic changes that confer CAM-DR.65-67 Adhesion of MM cells to BMSCs triggers nuclear factor {kappa}B (NF-{kappa}B)–dependent transcription and secretion of IL-6,76 whereas inhibition of NF-{kappa}B activity abrogates this response.77,78 Moreover, MM cells localized in the BM milieu secrete cytokines such as TNF{alpha},79 transforming growth factor {beta} (TGF-{beta}),80 and VEGF,81 which further up-regulate IL-6 secretion from BMSCs. Most importantly, within the BM microenvironment these cytokines mediate growth (IL-6, IGF-1, VEGF), survival (IL-6, IGF-1), drug resistance (IL-6, IGF-1, VEGF), and migration (IGF-1, VEGF, SDF-1{alpha}) of MM cells, and also trigger angiogenesis (VEGF) (Figure 4). Novel agents that can overcome CAM-DR and the growth advantage conferred in the BM in vitro, including thalidomide, immunomodulatory drugs (IMiDs), and proteasome inhibitors, hold great promise to overcome conventional drug resistance and improve patient outcome.73



View larger version (38K):
[in this window]
[in a new window]
  		Figure 4.. Interaction of MM cells and their BM milieu. Binding of MM cells to BMSCs triggers both adhesion- and cytokine-mediated MM cell growth, survival, drug resistance, and migration. MM cell binding to BMSCs up-regulates cytokine (IL-6, IGF-1, VEGF, SDF-1{alpha}) secretion from both BMSCs and MM cells. These cytokines subsequently activate 3 major signaling pathways (ERK, JAK/STAT3, and/or PI3-K/Akt), and their downstream targets including cytokines (IL-6, IGF-1, VEGF) and antiapoptotic proteins (Bcl-xL, IAPs, Mcl-1) in MM cells. Adhesion-mediated activation of NF-{kappa}B up-regulates adhesion molecules (ICAM-1, VCAM-1) on both MM cells and BMSCs, further enhancing adhesion of MM cells to BMSCs.

 

Since adhesion molecules play a central role in the pathogenesis of MM, therapeutic strategies targeting these molecules and the sequelae of adhesion have been developed and tested in animal models (ie, anti–ICAM-1 antibodies inhibit tumor development in severe combined immunodeficient [SCID] mice). In addition, SCID mice bearing human fetal bone grafts (SCID-hu mice) have been used to study in vivo homing and binding of human MM cells to human ECM proteins and BMSCs; related induction of human cytokines; associated tumor cell growth, survival, drug resistance, and migration; as well as evaluation of novel therapeutics.82-84 This model allows for direct evaluation of the impact of the human BM microenvironment and cytokines on tumor cell pathogenesis. Most recently, we have used green fluorescent protein (GFP)–labeled MM cells within a similar SCID mouse model to demonstrate that binding of MM cells in BM induces genes in tumor cells conferring growth, survival, drug resistance, and migration as well as genes in BMSCs modulating cytokines.85 This model allows for whole body imaging to assess tumor migration and localization in vivo. Moreover, evaluation of novel therapies in this model has identified agents (ie, IGF-1 and heat shock protein [Hsp] 90 inhibitors)86,87 with great promise to overcome drug resistance and improve patient outcome. One drawback of this model is the study of human MM cells in murine BM, given the lack of cross-reactivity of some murine cytokines with human tumor cells.

Role of cytokines in MM

IL-6

Although some MM cells secrete IL-6 and grow in an autocrine fashion,88 it is primarily produced in BMSCs89,90 and mediates paracrine MM cell growth. Its secretion is up-regulated in MM cells by CD40 activation91 and in BMSCs by either adhesion of MM cells or cytokines (TNF{alpha}, VEGF, IL-1{beta}).79,81,92 Binding of MM cells to BMSCs induces NF-{kappa}B activation and related up-regulation of IL-6 transcription and secretion in BMSCs; conversely, specific inhibition of NF-{kappa}B by I{kappa}B kinase (IKK) inhibitor down-regulates both constitutive and induced IL-6 secretion.78 CD45+ MM cells have recently been identified as those MM cells responsive to IL-6.93,94

IL-6 binds to gp80 (CD80, IL-6R) expressed on most MM cell lines and patient tumor cells, thereby inducing phosphorylation and homodimerization of gp130.95-98 Phosphorylation of gp130 in turn activates Ras/Raf/mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular signal-related kinase (ERK), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), and phosphatidylinositol-3 kinase (PI3-K)/Akt (PKB) downstream signaling pathways in MM cells (Figure 4) mediating MM cell growth, survival, and drug resistance, respectively.60,71,99-104 Targeted inhibition of Ras/Raf/MEK/ERK signaling using farnesyl-transferase inhibitor (R115777),102,103 ERK antisense oligonucleotide, and MEK1 inhibitor PD98059,100 or MEK1/2 inhibitor U0126,104 abrogates tumor cell growth. Survival and drug resistance of MM cells are mediated via activation of both JAK2/STAT3 and PI3-K/Akt signaling cascades. STAT3 regulates downstream protein expression of Bcl-2 family members Bcl-xL101 and Mcl-1,105-107 and expression of these antiapoptotic proteins can be selectively down-regulated by dominant/negative STAT3 or JAK inhibitor101,108,109 and antisense Mcl-1.110 Moreover, cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in MM cells, at least in part, by down-regulating Mcl-1.111 IL-6 confers resistance to dexamethasone (Dex),68,69,112 a common conventional therapy, via PI3-K/Akt signaling.60 Dex-mediated apoptosis in MM cells is associated with downstream release of second mitochondria activator of caspase (Smac), but not of cytochrome-c (cyto-c),113 from mitochondria114; cytosolic Smac disrupts X-linked inhibitor of apoptosis protein (XIAP)/caspase-9 complexes, thereby allowing activation of caspase-9, caspase-3 cleavage, and apoptosis. Since caspase-9 is a downstream target of Akt,115,116 IL-6 protects against Dex-induced apoptosis via inactivation of caspase-960; conversely, PI3-K inhibitors block IL-6–mediated protection against Dex-induced apoptosis.60,71 Recent studies show that X-box binding protein 1 (XBP-1), a transcription factor that induces differentiation of normal B cells to plasma cells, is induced by IL-6 in patient MM cells117-119; proteasome inhibitors act against MM cells, at least in part, by targeting XBP-1 and the unfolded protein response.120 Finally, it has shown that IL-6 induces caveolin-1 phosphorylation on the MM cell surface, whereas inhibition of caveolin-1 function blocks IL-6–mediated signaling and growth in MM cells.121

Clinically, serum IL-6 and IL-6 receptors (IL-6Rs) are prognostic factors in MM reflective of the proliferative fraction of tumor cells.122-124 Treatment strategies targeting IL-6 to date include antibodies to IL-6 and IL-6 receptor, as well as IL-6 superantagonists that compete for IL-6R binding but do not activate downstream signaling125-129; to date, however, only transient responses have been observed.

IGF-1

IGF-1 induces proliferation, survival, and drug resistance in MM cells via MEK/ERK and PI3-K/Akt signaling cascades. Although IGF-1 does not induce JAK2/STAT3 signaling in MM cells, it is a more potent inducer of Akt signaling than IL-6 and confers protection against Dex.71,130-132 IGF-1 triggers phosphorylation of FKHR (forkhead transcription factor); up-regulates intracellular antiapoptotic proteins including FLICE-inhibitory protein, survivin, cellular inhibitor of apoptosis protein 2, A1/Bfl-1, and XIAP132; and increases telomerase activity via induction of PI3-K/Akt/NF-{kappa}B signaling133 (Figure 4). Inhibitors of IGF-1 receptor demonstrate promising anti-MM activity in preclinical studies72; PI3-K or IKK inhibitors also block IGF-1–induced telomerase activity.133,134

VEGF

VEGF is produced in MM cells and BMSCs and accounts, at least in part, for increased angiogenesis in MM patient BM.135,136 Furthermore, both adhesion of MM cells to BMSCs and exogenous IL-6 up-regulate VEGF secretion, as does CD40 activation of human MM cells81,92,137 (Figure 4). VEGF triggers Flt-1 phosphorylation and activation of MEK/ERK and PI-3K/PKC{alpha} signaling cascades in MM cell lines and patient cells, thereby promoting modest proliferation and pronounced migration, respectively.138,139 These direct effects of VEGF on MM cells and BM angiogenesis suggest potential use of novel therapies targeting VEGF; already VEGF receptor tyrosine kinase inhibitor PTK787 has demonstrated promise in preclinical studies.140,141

TNF{alpha} and CD40 ligand

Both patient MM cells and BM mononuclear cells (BMMCs) express TNF{alpha} mRNA and protein,142-144 and TNF{alpha} secretion is significantly higher in those MM patients with bone disease.145 It induces tumor cell apoptosis via Fas-associated death domain/caspase-8 signaling,146,147 as well as survival via NF-{kappa}B activation and up-regulation of antiapoptotic proteins (ie, Bcl-xL, XIAP, inhibitor of apoptosis protein [IAP])148-151 (Figure 4). Combining TNF{alpha} inhibition with NF-{kappa}B blockade using IKK inhibitors enhances cytotoxicity.78 Although TNF{alpha} secreted by MM cells does not induce growth, survival, or drug resistance in tumor cells, it binds to a TNF{alpha} response element in the IL-6 promoter in BMSCs, and more potently triggers paracrine IL-6 transcription and secretion than does either VEGF or TGF-{beta}.79 Moreover, TNF{alpha} secreted by MM cells induces NF-{kappa}B–dependent up-regulation of adhesion molecules on both MM and BMSCs (CD49d, CD54),79 thereby increasing the binding of MM to BMSCs with associated CAM-DR and induction of cytokine (IL-6, IGF-1, VEGF) secretion in BMSCs.76,78,79 Novel agents targeting TNF{alpha}, including thalidomide and the IMiDs,152 act against MM, at least in part, by inhibiting sequelae of these induced cytokines.

CD40 ligand, a TNF{alpha} family member, modulates MM cell growth both directly and indirectly via its actions in the BM milieu.91,153,154 Specifically, activation of MM cells via CD40 directly triggers p53-dependent growth versus apoptosis, as well as PI3/Akt NF-{kappa}B–dependent MM cell migration.155 CD40 ligation also induces VEGF secretion in BMSCs, which mediates MM cell homing and migration as well as angiogenesis in the BM milieu.137 Finally, CD40 activation up-regulates both HLA and costimulatory molecules on MM cells, thereby augmenting their antigenpresenting capacity.

Other cytokines

Stromal cell–derived factor 1 {alpha} (SDF-1{alpha}), the ligand for chemokine receptor CXCR4, is present in supernatants from MM patient BMSCs, whereas CXCR4 is expressed on MM cells.156 SDF-1{alpha} transiently up-regulates VLA-4–mediated MM cell adhesion in the BM milieu,157 as well as inducing modest proliferation, migration, and protection against Dex-induced apoptosis via activation of ERK, PI3-K/Akt, and NF-{kappa}B signaling cascades, respectively.156 SDF-1{alpha} also induces secretion of IL-6 and VEGF in BMSCs, thereby further promoting MM cell growth, survival, drug resistance, and migration (Figure 4). Transforming growth factor beta (TGF-{beta}) secreted by MM cells triggers paracrine IL-6 secretion in BMSCs91; conversely, TGF-{beta} receptor inhibitors down-regulate IL-6 secretion in BMSCs and associated paracrine MM cell growth.158 IL-21 induces DNA synthesis in patient MM cells via phosphorylation of JAK1, STAT3, and ERK.159 B-cell stimulation factor 3 (BSF-3) triggers ERK and STAT3 phosphorylation, thereby stimulating growth and conferring Dex resistance in MM cells.160 IL-1, IL-6, receptor activator of NF-{kappa}B ligand (RANKL), parathyroid hormone-related protein (PTHrP), and macrophage inflammatory protein 1-{alpha} (MIP-1{alpha}) mediate bone destruction via activation of osteoclasts. RANKL triggers osteoclastogenesis and bone resorption as well as enhancing induction of osteoclasts by MIP-1{alpha} and/or IL-6.161-164 Most recently, increased Dickkopf 1 (DKK1) expression has been reported in MM cells, implicating Wnt signaling in suppression of osteoblasts and lytic lesions of bone in MM.58

Death signaling in MM

Both conventional and novel chemotherapeutic agents target specific kinases mediating MM cell growth, survival, and apoptosis.73 Most agents trigger apoptosis, which can be distinguished from necrosis by the lack of an associated inflammatory response.165 Cytosolic aspartate–specific proteases (CASPases), which disassemble cells into apoptotic bodies, are present as inactive proenzymes and commonly activated by proteolytic cleavage.166 In MM cells, caspase-8 is activated in response to extracellular apoptosis-inducing ligand (ie, TNF{alpha}, TRAIL), by cytoplasmic death domain (ie, Fas-associated death domain [FADD]),167 and by novel agents such as the immunomodulatory drug CC-5013 (lenalidomide, also known as Revimid or Revlimid)168 (Figure 5). On the other hand, caspase-9 is activated in response to agents that trigger release of cyto-c from mitochondria to the cytosol. Importantly, Dex-induced apoptosis in MM cells is associated with caspase-9 activation and release of second mitochondria-derived activator of caspases (Smac), but not cyto-c.114 Activation of either caspase-8 or caspase-9 is followed by downstream activation of caspase-3, poly adenosine diphosphate–ribose polymerase (PARP), and DNA fragmentation factor (DFF). Cross-talk of apoptotic signaling from caspase-8 to caspase-9 can occur (ie, via Bid).169,170 Furthermore, novel proteasome inhibitor bortezomib (Velcade), 2-methoxyestradiol (2ME2), and lysophosphatidic acid acyltransferase-{beta} (LPAAT-{beta}) inhibitors activate c-Jun NH2-terminal kinase (JNK), which translocates from cytosol to mitochondria, thereby facilitating release of mitochondrial cyto-c/Smac to the cytosol and sequential activation of caspases-9 and -3; conversely, blocking JNK using either specific JNK inhibitor SP600125 or dominant-negative JNK abrogates both stress-induced release of cyto-c/Smac and induction of apoptosis171-173 (Figure 5).



View larger version (24K):
[in this window]
[in a new window]
  		Figure 5.. Apoptotic signaling pathways triggered by conventional and novel therapies. Fas/FasL, TRAIL, Thal/IMiDs, and HDAC inhibitors trigger activation of caspase-8, whereas Dex activates caspase-9. Bortezomib (Velcade) and 2ME-2 induce both caspase-8 and -9 activation. Both IL-6 and IGF-1 inhibit caspase-9/caspase-3 apoptotic signaling via activation of Akt signaling.

 

Apoptosis can also be triggered or enhanced by down-regulation of inhibitor of apoptosis protein (IAP) activity (ie, inhibition of NF-{kappa}B activity down-regulates IAPs and enhances MM sensitivity to various drugs).168 Bcl-2 family proteins regulate the release of cyto-c from mitochondria to cytosol; inhibition of these proteins (ie, Bcl-2, Bcl-xL, Mcl-1) therefore also enhances sensitivity of MM cells to apoptotic stimuli.110,174 Importantly, these preclinical studies delineating apoptotic signaling induced by conventional and novel agents provide the framework for clinical treatment protocols. For example, both TRAIL and Revimid trigger caspase-8–mediated MM cell death168 and enhanced killing via intrinsic signaling in vitro, suggesting their potential combined clinical use (Figure 5). On the other hand, bortezomib induces predominantly activation of caspase-8, whereas Dex triggers activation of capase-9, providing the preclinical framework for combining agents in clinical protocols to induce dual apoptotic signaling. To date, thalidomide plus dexamethasone treatment has demonstrated significant antitumor activity against newly diagnosed175 as well as relapsed refractory MM.176 Bortezomib inhibits DNA repair by cleaving DNA-PKCs and ataxiatelangiectasia protein (ATM),171 thereby enhancing cytotoxicity or overcoming resistance to DNA damaging agents in vitro.177 Importantly, recent studies show that bortezomib can also overcome clinical resistance to doxorubicin and melphalan.178,179

Targeting the MM cell in its BM microenvironment

Both in vitro systems and in vivo animal models to characterize mechanisms of MM cell homing to BM have been developed, including the factors (MM cell–BMSCs interactions, cytokines, angiogenesis) promoting MM cell growth, survival, drug resistance, and migration in the BM milieu73 (Figure 6). These model systems have allowed for the development of several promising biologically based therapies that can target directly or indirectly both the MM cell and BM microenvironment including thalidomide/CC-5013 (Revimid),168,180-183 PS-341 (bortezomib),77,171,184-186 VEGF receptor kinase inhibitor PTK787,140 HDAC inhibitors SAHA187 and LAQ-824,188 2-ME2,118,189 arsenic trioxide,190 and LPAAT-{beta} inhibitor173; those that target MM cells including telomestatin,191 Hsp-90 inhibitor 17-AAG,87 TRAIL,168,192 statins,193 IGF-1R inhibitor72; and those that target only the BM microenvironment including I{kappa}B kinase inhibitors78 and p38MAPK inhibitors194 (Table 2). It is our hypothesis that drugs in these classes will need to be combined to achieve complete eradication of MM cells, and we are presently studying their mechanisms of action at a gene and protein level in order to provide the framework for rational combination clinical trials to overcome drug resistance and improve patient outcome.118



View larger version (28K):
[in this window]
[in a new window]
  		Figure 6.. Novel biologically based therapies targeting MM cells and the BM microenvironment. Novel agents (A) induce G1 growth arrest and/or apoptosis in MM cell lines and patient cells resistant to conventional chemotherapy; (B) inhibit MM cell adhesion to BMSCs; (C) decrease cytokine production and sequelae in the BM microenvironment; and (D) decrease angiogenesis.

 

View this table:
[in this window]
[in a new window]
  		Table 2.. Novel agents for myeloma

 

Having demonstrated preclinical promise of these novel agents, we have rapidly translated our laboratory studies to phase 1, 2, and 3 clinical trials to evaluate their clinical use and toxicity, and to move them rapidly from the bench to the bedside. Most excitingly, bortezomib195 and Revlimid196 have already demonstrated marked clinical anti-MM activity even in patients with refractory relapsed MM, confirming the use of our preclinical models to identify and validate novel therapeutics. Importantly, gene array and proteomic studies have helped to identify in vivo mechanisms of action and drug resistance, as well as aiding in their clinical application. For example, gene microarray profiling of bortezomib-treated MM cells reveals induction of heat shock protein 90 stress response,171,184 providing the rationale for the combined clinical use of bortezomib and 17-AAG to enhance anti-MM activity. The study of proteomics also forms the basis for clinical application. For example, protein profiling of bortezomib-treated MM cells demonstrated cleavage of DNA repair enzymes, providing the rationale for combining bortezomib with DNA damaging agents to enhance sensitivity or overcome resistance to these conventional therapies.177 These studies have provided the framework for a new treatment paradigm targeting MM cell-host BMSC interactions and their sequelae in the BM milieu to overcome drug resistance and improve patient outcome in MM.

Future directions

Recent studies have enabled the definition of molecular subtypes of MM and also the role of the BM milieu in pathogenesis. These studies have provided the framework for identification and validation of novel targeted therapies to overcome drug resistance and improve patient outcome. In the future, gene and protein profiling will enable patient-specific selection of targeted therapies197 and will also provide the framework for development of more potent and less toxic targeted therapies.


   Footnotes
 
Submitted January 9, 2004; accepted March 24, 2004.

Footnotes

Prepublished online as Blood First Edition Paper, April 15, 2004; DOI 10.1182/blood-2004-01-0037.

Supported by National Institutes of Health Grant Specialized Programs of Research Excellence (SPORE) IP50 CA10070-01, PO-1 78378, and RO-1 CA 50947; the Doris Duke Distinguished Clinical Research Scientist Award; the Multiple Myeloma Research Foundation; and the Cure for Myeloma Research Fund.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

Reprints: Kenneth C. Anderson, Dana-Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115; e-mail: kenneth_anderson{at}dfci.harvard.edu.

References

  1. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute; 2002.

  2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among Olmsted County, MN residents over 50 years of age [abstract]. Blood. 2003;102: 3476a.

  3. Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101: 3801-3808.[Abstract/Free Full Text]

  4. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346: 564-569.[Abstract/Free Full Text]

  5. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med. 1998;104: 439-444.[CrossRef][Medline] [Order article via Infotrieve]

  6. Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst. 2001;93: 1479-1483.[Abstract/Free Full Text]

  7. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113: 73-77.[CrossRef][Medline] [Order article via Infotrieve]

  8. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2: 175-187.[CrossRef][Medline] [Order article via Infotrieve]

  9. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20: 5611-5622.[CrossRef][Medline] [Order article via Infotrieve]

  10. Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101: 7-11.[CrossRef][Medline] [Order article via Infotrieve]

  11. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59: 4546-4550.[Abstract/Free Full Text]

  12. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99: 2185-2191.[Abstract/Free Full Text]

  13. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101: 4569-4575.[Abstract/Free Full Text]

  14. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002; 100: 1417-1424.[Abstract/Free Full Text]

  15. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology (Am Soc Hematol Educ Program). 2002: 214-240.

  16. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res. 2002;62: 715-720.[Abstract/Free Full Text]

  17. Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 1998;92: 4269-4278.[Abstract/Free Full Text]

  18. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001; 112: 167-174.[CrossRef][Medline] [Order article via Infotrieve]

  19. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma: association with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genetics. 1997;16: 260-264.[CrossRef][Medline] [Order article via Infotrieve]

  20. Chesi M, Nardini E, Lim RSC, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92: 3025-3034.[Abstract/Free Full Text]

  21. Chesi M, Bergsagel PL, Kuehl WM. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol. 2002;9: 288-293.[CrossRef][Medline] [Order article via Infotrieve]

  22. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101: 1520-1529.[Abstract/Free Full Text]

  23. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003;101: 2374-2376.[Abstract/Free Full Text]

  24. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100: 1579-1583.[Abstract/Free Full Text]

  25. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98: 3082-3086.[Abstract/Free Full Text]

  26. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A. 2000;97: 228-233.[Abstract/Free Full Text]

  27. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003; 194: 96-104.[CrossRef][Medline] [Order article via Infotrieve]

  28. Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002;100: 1113-1122.

  29. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99: 1745-1757.[Abstract/Free Full Text]

  30. Shaughnessy J Jr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98: 217-223.[Abstract/Free Full Text]

  31. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98: 2229-2238.[Abstract/Free Full Text]

  32. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer. 2003;38: 234-239.[CrossRef][Medline] [Order article via Infotrieve]

  33. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102: 2562-2567.[Abstract/Free Full Text]

  34. Urashima M, Teoh G, Ogata A, et al. Characterization of p16INK4A expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res. 1997;3: 2173-2179.[Abstract]

  35. Guillerm G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001;98: 244-246.[Abstract/Free Full Text]

  36. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mut. 2001;18: 212-224.[CrossRef][Medline] [Order article via Infotrieve]

  37. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88: 2699-2706.[Abstract/Free Full Text]

  38. Fonseaca R, Price-Troska T, Blood E, et al. Implication of N-ras and K-ras mutation in clinical outcome and biology of multiple myeloma [abstract]. Blood. 2003;102: 113a.

  39. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92: 802-809.[Abstract/Free Full Text]

  40. Juge-Morineau N, Harousseau JL, Amiot M, Bataille R. The retinoblastoma susceptibility gene RB-1 in multiple myeloma. Leuk Lymphoma. 1997;24: 229-237.[Medline] [Order article via Infotrieve]

  41. Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia. 2002;16: 127-134.[CrossRef][Medline] [Order article via Infotrieve]

  42. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood. 2000;96: 3560-3568.[Abstract/Free Full Text]

  43. Ge NL, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene. 2000;19: 4091-4095.[CrossRef][Medline] [Order article via Infotrieve]

  44. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5: 191-199.[CrossRef][Medline] [Order article via Infotrieve]

  45. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101: 3849-3856.[Abstract/Free Full Text]

  46. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102: 1588-1594.[Abstract/Free Full Text]

  47. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia. 2003;17: 2032-2035.[CrossRef][Medline] [Order article via Infotrieve]

  48. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101: 1570-1571.[Abstract/Free Full Text]

  49. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99: 3735-3741.[Abstract/Free Full Text]

  50. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1: 222-231.[CrossRef][Medline] [Order article via Infotrieve]

  51. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Canc Agents. 2003;3: 187-199.[CrossRef]

  52. Caraglia M, Tagliaferri P, Budillon A, Abbruzzese A. Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. Adv Exp Med Biol. 1999;472: 187-198.[Medline] [Order article via Infotrieve]

  53. Palakurthi SS, Fluckiger R, Aktas H, et al. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. 2000;60: 2919-2925.[Abstract/Free Full Text]

  54. Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E. Cyclin proteolysis as a retinoid cancer prevention mechanism. Ann N Y Acad Sci. 2001;952: 13-22.[Medline] [Order article via Infotrieve]

  55. Tsutsumi S, Yanagawa T, Shimura T, et al. Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem. 2003;278: 32165-32172.[Abstract/Free Full Text]

  56. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2: 103-112.[CrossRef][Medline] [Order article via Infotrieve]

  57. Trudel S, Ely SA, Farooqi Y, et al. Inhibition of fibroblast growth factor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. Prepublished on January 8, 2004, as DOI 10.1182/blood-2003-10-3650. (Now available as Blood. 2004; 103:3521-3528.)

  58. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349: 2483-2494.[Abstract/Free Full Text]

  59. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97: 1566-1571.[Abstract/Free Full Text]

  60. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20: 5991-6000.[CrossRef][Medline] [Order article via Infotrieve]

  61. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12: 3499-3511.[Abstract/Free Full Text]

  62. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19: 2690-2698.[Abstract/Free Full Text]

  63. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19: 5785-5799.[Abstract/Free Full Text]

  64. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997;11: 27-42.[CrossRef][Medline] [Order article via Infotrieve]

  65. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93: 1658-1667.[Abstract/Free Full Text]

  66. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;19: 4319-4327.[CrossRef][Medline] [Order article via Infotrieve]

  67. Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003;63: 7900-7906.[Abstract/Free Full Text]

  68. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162: 248-255.[CrossRef][Medline] [Order article via Infotrieve]

  69. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997;15: 837-843.[CrossRef][Medline] [Order article via Infotrieve]

  70. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89: 227-234.[Abstract/Free Full Text]

  71. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60: 6763-6770.[Abstract/Free Full Text]

  72. Mitsiades CS, Mitsiades N, Kung AL, et al. The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors [abstract]. Blood. 2002; 100: 170a.

  73. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2: 927-937.[CrossRef][Medline] [Order article via Infotrieve]

  74. Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood. 1998; 91: 2679-2688.[Abstract/Free Full Text]

  75. Kaushal GP, Xiong X, Athota AB, Rozypal TL, Sanderson RD, Kelly T. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. Br J Haematol. 1999;104: 365-373.[CrossRef][Medline] [Order article via Infotrieve]

  76. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kB. Blood. 1996;87: 1104-1112.[Abstract/Free Full Text]

  77. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61: 3071-3076.[Abstract/Free Full Text]

  78. Hideshima T, Chauhan D, Richardson P, et al. NF-kB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277: 16639-16647.[Abstract/Free Full Text]

  79. Hideshima T, Chauhan D, Schlossman RL, Richardson PR, Anderson KC. Role of TNF-a in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20: 4519-4527.[CrossRef][Medline] [Order article via Infotrieve]

  80. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor b1: Differential effects on multiple myeloma versus normal B cells. Blood. 1996;87: 1928-1938.[Abstract/Free Full Text]

  81. Dankar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95: 2630-2636.[Abstract/Free Full Text]

  82. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997; 90: 754-765.[Abstract/Free Full Text]

  83. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growting in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92: 2908-2913.[Abstract/Free Full Text]

  84. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002;100: 4162-4168.[Abstract/Free Full Text]

  85. Mitsiades CS, Mitsiades N, McMullan CJ, et al. In vitro and in vivo molecular profiling of multiple myeloma (MM) cell interaction with bone marrow (BM) microenvironment: insight into the role of novel anti-MM agents in counteracting BM-mediated drug-resistance in MM [abstract]. Blood. 2003;102: 441a.

  86. Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003;63: 6689-6696.[Abstract/Free Full Text]

  87. Mitsiades CS, Mitsiades N, Poulaki V, Akiyama M, Treon SP, Anderson KC. The HSP90 molecular chaperone as a novel therapeutic target in hematologic malignancies [abstract]. Blood. 2001; 98: 377a.

  88. Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Int J Cancer. 1996;65: 498-505.[CrossRef][Medline] [Order article via Infotrieve]

  89. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73: 517-526.[Abstract/Free Full Text]

  90. Ballester OF, Moscinski LC, Lyman GH, et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood. 1994;83: 1903-1908.[Abstract/Free Full Text]

  91. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995; 85: 1903-1912.[Abstract/Free Full Text]

  92. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15: 1950-1961.[Medline] [Order article via Infotrieve]

  93. Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood. 2002;15: 2172-2178.

  94. Bataille R, Robillard N, Pellat-Deceunynck C, Amiot M. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev. 2003;194: 105-111.[CrossRef][Medline] [Order article via Infotrieve]

  95. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58: 573-581.[CrossRef][Medline] [Order article via Infotrieve]

  96. Nishimoto N, Ogata A, Shima Y, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med. 1994;179: 1343-1347.[Abstract/Free Full Text]

  97. Matsuda T, Fukada T, Takahashi-Tezuka M, et al. Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association. J Biol Chem. 1995;270: 11037-11039.[Abstract/Free Full Text]

  98. Kurth I, Horsten U, Pflanz S, et al. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes. J Immunol. 1999;162: 1480-1487.[Abstract/Free Full Text]

  99. Neumann C, Zehentmaier G, Danhauser-Riedl S, Emmerich B, Hallek M. Interleukin-6 induces tyrosine phosphorylation of the Ras activating protein Shc, and its complex formation with Grb2 in the human multiple myeloma cell line LP-1. Eur J Immunol. 1996;26: 379-384.[Medline] [Order article via Infotrieve]

  100. Ogata A, Chauhan D, Teoh G, et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159: 2212-2221.[Abstract/Free Full Text]

  101. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of STAT-3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10: 105-115.[CrossRef][Medline] [Order article via Infotrieve]

  102. Ochiai N, Uchida R, Fuchida S, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood. 2003;102: 3349-3353.[Abstract/Free Full Text]

  103. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101: 1692-1697.[Abstract/Free Full Text]

  104. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101: 3126-3135.[Abstract/Free Full Text]

  105. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29: 3945-3950.[CrossRef][Medline] [Order article via Infotrieve]

  106. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99: 1885-1893.[Abstract/Free Full Text]

  107. Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene. 2003;22: 2950-2959.[CrossRef][Medline] [Order article via Infotrieve]

  108. Oshiro MM, Landowski TH, Catlett-Falcone R, et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res. 2001;7: 4262-4271.[Abstract/Free Full Text]

  109. Zhang B, Potyagaylo V, Fenton RG. IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene. 2003;22: 1848-1859.[CrossRef][Medline] [Order article via Infotrieve]

  110. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100: 194-199.[Abstract/Free Full Text]

  111. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8: 3527-3538.[Abstract/Free Full Text]

  112. Hardin J, Macleod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84: 3063-3070.[Abstract/Free Full Text]

  113. Chauhan D, Pandey P, Ogata A, et al. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells. J Biol Chem. 1997;272: 29995-29997.[Abstract/Free Full Text]

  114. Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S, Anderson KC. Apaf-1/cytochrome c independent and Smac dependent induction of apoptosis in multiple myeloma cells. J Biol Chem. 2001;276: 24453-24456.[Abstract/Free Full Text]

  115. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282: 1318-1321.[Abstract/Free Full Text]

  116. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96: 857-868.[CrossRef][Medline] [Order article via Infotrieve]

  117. Wen XY, Stewart AK, Sooknanan RR, et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol. 1999;15: 173-178.[Medline] [Order article via Infotrieve]

  118. Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003;101: 3606-3614.[Abstract/Free Full Text]

  119. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412: 300-307.[CrossRef][Medline] [Order article via Infotrieve]

  120. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003;100: 9946-9951.[Abstract/Free Full Text]

  121. Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003;278: 5794-5801.[Abstract/Free Full Text]

  122. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol. 1996;92: 370-374.[CrossRef][Medline] [Order article via Infotrieve]

  123. Kyrtsonis MC, Dedoussis G, Zervas C, et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 1996;93: 398-400.[CrossRef][Medline] [Order article via Infotrieve]

  124. Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer. 1998;82: 1860-1866.[CrossRef][Medline] [Order article via Infotrieve]

  125. Huang YW, Vitetta ES. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Hybridoma. 1993;12: 621-630.[Medline] [Order article via Infotrieve]

  126. Savino R, Ciapponi L, Lahm A, et al. Rational design of a receptor super-antagonist of human interleukin-6. Embo J. 1994;13: 5863-5870.[Medline] [Order article via Infotrieve]

  127. Montero-Julian FA, Klein B, Gautherot E, Brailly H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood. 1995;85: 917-924.[Abstract/Free Full Text]

  128. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol. 1995;154: 4091-4098.[Abstract]

  129. Demartis A, Bernassola F, Savino R, Melins G, Ciliberto G. Interleukin-6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res. 1996;56: 4213-4218.[Abstract/Free Full Text]

  130. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 2000;96: 2856-2861.[Abstract/Free Full Text]

  131. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood. 2002;99: 4138-4146.[Abstract/Free Full Text]

  132. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21: 5673-5683.[CrossRef][Medline] [Order article via Infotrieve]

  133. Akiyama M, Hideshima T, Hayashi T, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002;62: 3876-3882.[Abstract/Free Full Text]

  134. Akiyama M, Hideshima T, Hayashi T, et al. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003;63: 18-21.[Abstract/Free Full Text]

  135. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol. 2001;28: 560-564.[CrossRef][Medline] [Order article via Infotrieve]

  136. Xu JL, Lai R, Kinoshita T, Nakashima N, Nagasaka T. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol. 2002;55: 530-534.[Abstract/Free Full Text]

  137. Tai YT, Podar K, Gupta D, et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood. 2002;99: 1419-1427.[Abstract/Free Full Text]

  138. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98: 428-435.[Abstract/Free Full Text]

  139. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002;277: 7875-7881.[Abstract/Free Full Text]

  140. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002;62: 5019-5026.[Abstract/Free Full Text]

  141. Podar K, Catley LP, Tai YT, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Prepublished on November 26, 2003, as DOI 10.1182/blood-2003-10-3527. (Now available as Blood. 2004;103:3474-3479.)

  142. Garrett IR, Durie BG, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987;317: 526-532.[Abstract]

  143. Lichtenstein A, Berenson D, Norman MP, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood. 1989;74: 1266-1273.[Abstract/Free Full Text]

  144. Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev. 1996;20: 52-56.[Medline] [Order article via Infotrieve]

  145. Davies FE, Rollinson SJ, Rawstron AC, et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol. 2000;18: 2843-2851.[Abstract/Free Full Text]

  146. Bang S, Jeong EJ, Kim IK, Jung YK, Kim KS. Fas- and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction. A typical model for convergent signal transduction. J Biol Chem. 2000;2000: 36217-36222.

  147. Qin ZH, Wang Y, Kikly KK, et al. Pro-caspase-8 is predominantly localized in mitochondria and released into cytoplasm upon apoptotic stimulation. J Biol Chem. 2001;276: 8079-8086.[Abstract/Free Full Text]

  148. Badrichani AZ, Stroka DM, Bilbao G, Curiel DT, Bach FH, Ferran C. Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB. J Clin Invest. 1999;103: 543-553.[Medline] [Order article via Infotrieve]

  149. Tsukahara T, Kannagi M, Ohashi T, et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol. 1999;73: 7981-7987.[Abstract/Free Full Text]

  150. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998;188: 211-216.[Abstract/Free Full Text]

  151. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998; 281: 1680-1683.[Abstract/Free Full Text]

  152. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J Immunol. 1999; 163: 380-386.[Abstract/Free Full Text]

  153. Westendorf J, Ahmann G, Armitage R, et al. CD40 expression in malignant plasma cells: Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 1994;152: 117-128.[Abstract]

  154. Teoh G, Tai YT, Urashima M, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000;95: 1039-1046.[Abstract/Free Full Text]

  155. Tai YT, Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003;101: 2762-2769.[Abstract/Free Full Text]

  156. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1: 539-544.[Abstract/Free Full Text]

  157. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001;97: 346-351.[Abstract/Free Full Text]

  158. Hayashi T, Hideshima T, Podar K, et al. TGF-b receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell proliferation in the bone marrow microenvironment [abstract]. Blood. 2003;102: 388b.[CrossRef]

  159. Brenne AT, Baade Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. 2002;99: 3756-3762.[Abstract/Free Full Text]

  160. Burger R, Bakker F, Guenther A, et al. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol. 2003;123: 869-878.[CrossRef][Medline] [Order article via Infotrieve]

  161. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993;90: 11924-11928.[Abstract/Free Full Text]

  162. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol. 2001;19: 3562-3571.[Abstract/Free Full Text]

  163. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003;101: 2094-2099.[Abstract/Free Full Text]

  164. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423: 337-342.[CrossRef][Medline] [Order article via Infotrieve]

  165. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology. 2003;125: 1246-1257.[CrossRef][Medline] [Order article via Infotrieve]

  166. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281: 1312-1318.[Abstract/Free Full Text]

  167. Chauhan D, Hideshima T, Anderson KC. Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol. 2003;78: 114-120.[Medline] [Order article via Infotrieve]

  168. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99: 4525-4530.[Abstract/Free Full Text]

  169. Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001;98: 2183-2192.[Abstract/Free Full Text]

  170. Dai Y, Dent P, Grant S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. Mol Pharmacol. 2003;64: 1402-1409.[Abstract/Free Full Text]

  171. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101: 1530-1534.[Abstract/Free Full Text]

  172. Chauhan D, Li G, Hideshima T, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003;278: 17593-17596.[Abstract/Free Full Text]

  173. Hideshima T, Chauhan D, Hayashi T, et al. Antitumor activity of lysophosphatidic acid acyltransferase (LPAAT)-b inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003; 63: 8428-8436.[Abstract/Free Full Text]

  174. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ. 2000;7: 1244-1252.[CrossRef][Medline] [Order article via Infotrieve]

  175. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20: 4319-4323.[Abstract/Free Full Text]

  176. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21: 16-19.[Abstract/Free Full Text]

  177. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101: 2377-2380.[Abstract/Free Full Text]

  178. Orlowski RZ, Hall M, Voorhees P, et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade) in combination with pegylated liposomal doxorubicin (Doxil) in patients with refractory helatologic malignancies [abstract]. Blood. 2002;100: 105a.

  179. Yang HH, Swift R, Sadler K, et al. A phase I/II trial of VelcadeTM and melphalan combination therapy (Ve+M) for patients with relapsed or refractory multiple myeloma (MM) [abstract]. Blood. 2003; 102: 235a.

  180. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96: 2943-2950.[Abstract/Free Full Text]

  181. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98: 210-216.[Abstract/Free Full Text]

  182. Lentzsch S, LeBlanc R, Podar K, et al. Immunodulatory analogs of thalidomide inhibit growth of HS Sultan cells and angiogenesis in vivo. Leukemia. 2003;17: 41-44.[CrossRef][Medline] [Order article via Infotrieve]

  183. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102: 1435-1442.[Abstract/Free Full Text]

  184. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99: 14374-14379.[Abstract/Free Full Text]

  185. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62: 4996-5000.[Abstract/Free Full Text]

  186. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003;22: 8386-8393.[CrossRef][Medline] [Order article via Infotrieve]

  187. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101: 4055-4062.[Abstract/Free Full Text]

  188. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102: 2615-2622.[Abstract/Free Full Text]

  189. Chauhan D, Catley L, Hideshima T, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002;100: 2187-2194.[Abstract/Free Full Text]

  190. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1: 851-860.[Abstract/Free Full Text]

  191. Shammas MA, Shmookler Reis RJ, Koley H, et al. Telomerase inhibition and apoptotic cell death following Telomestatin treatment of multiple myeloma [abstract]. Blood. 2002;100: 810a.

  192. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001; 98: 795-804.[Abstract/Free Full Text]

  193. Mitsiades CS, Mitsiades N, Poulaki V, et al. HMG-CoA inhibitors (statins) induce growth arrest, apoptosis of multiple myeloma (MM) and Waldenstrom's Macroglobulinemia (WM) cells and enhance their sensitivity to conventional or novel therapies. Molecular profiling of HMG-CoA inhibition in MM/WM and framework for translation to therapeutic application [abstract]. Blood. 2002; 100: 597a.

  194. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003; 101: 703-705.[Abstract/Free Full Text]

  195. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348: 2609-2617.[Abstract/Free Full Text]

  196. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100: 3063-3067.[Abstract/Free Full Text]

  197. Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004;103: 1799-1806.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
Y. Hu, K. Kirito, K. Yoshida, T. Mitsumori, K. Nakajima, Y. Nozaki, S. Hamanaka, T. Nagashima, M. Kunitama, K. Sakoe, et al.
Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan
Mol. Cancer Ther., August 1, 2009; 8(8): 2329 - 2338.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Nojima, R. Maruyama, H. Yasui, H. Suzuki, Y. Maruyama, I. Tarasawa, Y. Sasaki, H. Asaoku, H. Sakai, T. Hayashi, et al.
Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
Clin. Cancer Res., July 1, 2009; 15(13): 4356 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J.-L. Harousseau and P. Moreau
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654.
[Full Text] [PDF]

Home page
 BloodHome page
O. Landgren, R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, et al.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Blood, May 28, 2009; 113(22): 5412 - 5417.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Kitatani, K. Sheldon, V. Anelli, R. W. Jenkins, Y. Sun, G. A. Grabowski, L. M. Obeid, and Y. A. Hannun
Acid {beta}-Glucosidase 1 Counteracts p38{delta}-dependent Induction of Interleukin-6: POSSIBLE ROLE FOR CERAMIDE AS AN ANTI-INFLAMMATORY LIPID
J. Biol. Chem., May 8, 2009; 284(19): 12979 - 12988.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. M. Matulis, A. A. Morales, L. Yehiayan, C. Croutch, D. Gutman, Y. Cai, K. P. Lee, and L. H. Boise
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line
Mol. Cancer Ther., May 1, 2009; 8(5): 1197 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Azab, J. M. Runnels, C. Pitsillides, A.-S. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, B. Ospina, A. L. Carlson, et al.
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Blood, April 30, 2009; 113(18): 4341 - 4351.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-T. Tai, E. Soydan, W. Song, M. Fulciniti, K. Kim, F. Hong, X.-F. Li, P. Burger, M. J. Rumizen, S. Nahar, et al.
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
Blood, April 30, 2009; 113(18): 4309 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hornakova, J. Staerk, Y. Royer, E. Flex, M. Tartaglia, S. N. Constantinescu, L. Knoops, and J.-C. Renauld
Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor {alpha} Homodimers
J. Biol. Chem., March 13, 2009; 284(11): 6773 - 6781.
[Abstract] [Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
P. A Engel and C. Lee
Sudden appearance and spontaneous regression of diffuse large B cell lymphoma in a man with a broken arm
BMJ Case Reports, March 5, 2009; 2009(mar02_1): bcr1020081036 - bcr1020081036.
[Abstract] [Full Text]

Home page
 BloodHome page
Y. Okawa, T. Hideshima, P. Steed, S. Vallet, S. Hall, K. Huang, J. Rice, A. Barabasz, B. Foley, H. Ikeda, et al.
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Blood, January 22, 2009; 113(4): 846 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Burger, S. Le Gouill, Y.-T. Tai, R. Shringarpure, P. Tassone, P. Neri, K. Podar, L. Catley, T. Hideshima, D. Chauhan, et al.
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Mol. Cancer Ther., January 1, 2009; 8(1): 26 - 35.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Zollinger, T. Stuhmer, M. Chatterjee, S. Gattenlohner, E. Haralambieva, H.-K. Muller-Hermelink, M. Andrulis, A. Greiner, C. Wesemeier, J. C. Rath, et al.
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
Blood, October 15, 2008; 112(8): 3403 - 3411.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al.
Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Blood, August 15, 2008; 112(4): 1346 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Mao, S.-b. Liang, R. Hurren, M. Gronda, S. Chow, G. W. Xu, X. Wang, R. B. Zavareh, N. Jamal, H. Messner, et al.
Cyproheptadine displays preclinical activity in myeloma and leukemia
Blood, August 1, 2008; 112(3): 760 - 769.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, and C. Pellat-Deceunynck
Osteoclasts support the survival of human plasma cells in vitro
Int. Immunol., June 1, 2008; 20(6): 775 - 782.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al.
Targeting NF-{kappa}B in Waldenstrom macroglobulinemia
Blood, May 15, 2008; 111(10): 5068 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. A. Morales, D. Gutman, K. P. Lee, and L. H. Boise
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma
Blood, May 15, 2008; 111(10): 5152 - 5162.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
O. Landgren, L. R. Goldin, N. E. Caporaso, R. A. Kyle, and S. V. Rajkumar
Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance-reply-I
Mayo Clin. Proc., May 1, 2008; 83(5): 602 - 603.
[Full Text] [PDF]

Home page
 BloodHome page
M. Chatterjee, C. Rancso, T. Stuhmer, N. Eckstein, M. Andrulis, C. Gerecke, H. Lorentz, H.-D. Royer, and R. C. Bargou
The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma
Blood, April 1, 2008; 111(7): 3714 - 3722.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Huston, X. Leleu, X. Jia, A.-S. Moreau, H. T. Ngo, J. Runnels, J. Anderson, Y. Alsayed, A. Roccaro, S. Vallet, et al.
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
Clin. Cancer Res., February 1, 2008; 14(3): 865 - 874.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al.
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood, January 15, 2008; 111(2): 806 - 815.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Lauring, A. M. Abukhdeir, H. Konishi, J. P. Garay, J. P. Gustin, Q. Wang, R. J. Arceci, W. Matsui, and B. H. Park
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
Blood, January 15, 2008; 111(2): 856 - 864.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C. E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.-B. Rios, L. Calvert, et al.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Mol. Cancer Ther., January 1, 2008; 7(1): 48 - 58.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Blood, December 15, 2007; 110(13): 4417 - 4426.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
O. Landgren, J. A. Katzmann, A. W. Hsing, R. M. Pfeiffer, R. A. Kyle, E. D. Yeboah, R. B. Biritwum, Y. Tettey, A. A. Adjei, D. R. Larson, et al.
Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana
Mayo Clin. Proc., December 1, 2007; 82(12): 1468 - 1473.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase
Cancer Res., October 15, 2007; 67(20): 9913 - 9920.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Brousseau, X. Leleu, J. Gerard, T. Gastinne, A. Godon, F. Genevieve, M. Dib, J.-L. Lai, T. Facon, M. Zandecki, et al.
Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients
Clin. Cancer Res., October 15, 2007; 13(20): 6026 - 6031.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
Clin. Cancer Res., October 15, 2007; 13(20): 6162 - 6167.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-T. Tai, M. Fulciniti, T. Hideshima, W. Song, M. Leiba, X.-F. Li, M. Rumizen, P. Burger, A. Morrison, K. Podar, et al.
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Blood, September 1, 2007; 110(5): 1656 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al.
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
Blood, July 15, 2007; 110(2): 709 - 718.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Blood, July 1, 2007; 110(1): 296 - 304.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C.-S. Chim, R. Liang, T.-K. Fung, C.-L. Choi, and Y.-L. Kwong
Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma
J. Clin. Pathol., June 1, 2007; 60(6): 664 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al.
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Mol. Cancer Ther., June 1, 2007; 6(6): 1718 - 1727.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Hatjiharissi, H. Ngo, A. A. Leontovich, X. Leleu, M. Timm, M. Melhem, D. George, G. Lu, J. Ghobrial, Y. Alsayed, et al.
Proteomic Analysis of Waldenstrom Macroglobulinemia
Cancer Res., April 15, 2007; 67(8): 3777 - 3784.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Blood, April 15, 2007; 109(8): 3177 - 3188.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Blood, April 15, 2007; 109(8): 3489 - 3495.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. J. Chng, S. Kumar, S. VanWier, G. Ahmann, T. Price-Troska, K. Henderson, T.-H. Chung, S. Kim, G. Mulligan, B. Bryant, et al.
Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
Cancer Res., April 1, 2007; 67(7): 2982 - 2989.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
L. Cook and D. H C Macdonald
Management of paraproteinaemia
Postgrad. Med. J., April 1, 2007; 83(978): 217 - 223.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Landgren, J. S. Rapkin, N. E. Caporaso, L. Mellemkjaer, G. Gridley, L. R. Goldin, and E. A. Engels
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia
Blood, March 1, 2007; 109(5): 2198 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Chatterjee, S. Jain, T. Stuhmer, M. Andrulis, U. Ungethum, R.-J. Kuban, H. Lorentz, K. Bommert, M. Topp, D. Kramer, et al.
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90{alpha} and {beta} in multiple myeloma cells, which critically contribute to tumor-cell survival
Blood, January 15, 2007; 109(2): 720 - 728.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. Agnelli, S. Bicciato, S. Fabris, L. Baldini, F. Morabito, D. Intini, D. Verdelli, A. Callegaro, F. Bertoni, G. Lambertenghi-Deliliers, et al.
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma
Haematologica, January 1, 2007; 92(1): 56 - 65.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C.-S. Chim, R. Liang, M.-H. Leung, and Y.-L. Kwong
Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma
J. Clin. Pathol., January 1, 2007; 60(1): 104 - 106.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327.
[Full Text] [PDF]

Home page
 NEJMHome page
J. Blade
Monoclonal Gammopathy of Undetermined Significance
N. Engl. J. Med., December 28, 2006; 355(26): 2765 - 2770.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. LeGouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L. N. Pandite, et al.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
PNAS, December 19, 2006; 103(51): 19478 - 19483.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Wang, S. Hong, J. Yang, J. Qian, X. Zhang, E. Shpall, L. W. Kwak, and Q. Yi
Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells
Blood, December 15, 2006; 108(13): 4071 - 4077.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
O. Landgren, Y. Zhang, S. H. Zahm, P. Inskip, T. Zheng, and D. Baris
Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2342 - 2347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. K. Francis, Y. Alsayed, X. Leleu, X. Jia, U. K. Singha, J. Anderson, M. Timm, H. Ngo, G. Lu, A. Huston, et al.
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma.
Clin. Cancer Res., November 15, 2006; 12(22): 6826 - 6835.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. J. Chng, R. F. Schop, T. Price-Troska, I. Ghobrial, N. Kay, D. F. Jelinek, M. A. Gertz, A. Dispenzieri, M. Lacy, R. A. Kyle, et al.
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Blood, October 15, 2006; 108(8): 2755 - 2763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al.
MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo.
Clin. Cancer Res., October 1, 2006; 12(19): 5887 - 5894.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. R. Cook, M. Hartke, J. Pettay, and R. R. Tubbs
Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous CD138 Immunofluorescence
J. Mol. Diagn., September 1, 2006; 8(4): 459 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Nadav, B.-Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger
The Generation and Regulation of Functional Diversity of Malignant Plasma Cells.
Cancer Res., September 1, 2006; 66(17): 8608 - 8616.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Li, S. Cortez, T. Nakamachi, V. Batuman, and A. Arimura
Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells.
Cancer Res., September 1, 2006; 66(17): 8796 - 8803.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Vacca, C. Scavelli, G. Serini, G. Di Pietro, T. Cirulli, F. Merchionne, D. Ribatti, F. Bussolino, D. Guidolin, G. Piaggio, et al.
Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma
Blood, September 1, 2006; 108(5): 1661 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Menoret, P. Gomez-Bougie, A. Geffroy-Luseau, S. Daniels, P. Moreau, S. Le Gouill, J.-L. Harousseau, R. Bataille, M. Amiot, and C. Pellat-Deceunynck
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
Blood, August 15, 2006; 108(4): 1346 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. S. El-Deiry, C. C. Sigman, and G. J. Kelloff
Imaging and Oncologic Drug Development
J. Clin. Oncol., July 10, 2006; 24(20): 3261 - 3273.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-T. Tai, X.-F. Li, I. Breitkreutz, W. Song, P. Neri, L. Catley, K. Podar, T. Hideshima, D. Chauhan, N. Raje, et al.
Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.
Cancer Res., July 1, 2006; 66(13): 6675 - 6682.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood, May 15, 2006; 107(10): 4053 - 4062.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. M. Rigolin, C. Fraulini, M. Ciccone, E. Mauro, A. M. Bugli, C. De Angeli, M. Negrini, A. Cuneo, and G. Castoldi
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
Blood, March 15, 2006; 107(6): 2531 - 2535.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Takebe, X. Cheng, T. E. Fandy, R. K. Srivastava, S. Wu, S. Shankar, K. Bauer, J. Shaughnessy, and G. Tricot
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Mol. Cancer Ther., February 1, 2006; 5(2): 457 - 466.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Landgren, G. Gridley, I. Turesson, N. E. Caporaso, L. R. Goldin, D. Baris, T. R. Fears, R. N. Hoover, and M. S. Linet
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
Blood, February 1, 2006; 107(3): 904 - 906.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al.
Antimyeloma activity of heat shock protein-90 inhibition
Blood, February 1, 2006; 107(3): 1092 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al.
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Blood, January 15, 2006; 107(2): 655 - 660.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al.
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
Blood, January 15, 2006; 107(2): 669 - 678.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. H. Prabhala, P. Neri, J. E. Bae, P. Tassone, M. A. Shammas, C. K. Allam, J. F. Daley, D. Chauhan, E. Blanchard, H. S. Thatte, et al.
Dysfunctional T regulatory cells in multiple myeloma
Blood, January 1, 2006; 107(1): 301 - 304.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
Blood, December 15, 2005; 106(13): 4322 - 4329.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, T. C. Chen, and A. H. Schonthal
Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib
Blood, December 15, 2005; 106(13): 4330 - 4338.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, A. Zanella, et al.
Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1548 - 1548.
[Abstract]

Home page
 Clin. Cancer Res.Home page
R. K. Thomas, M. L. Sos, T. Zander, O. Mani, A. Popov, D. Berenbrinker, S. Smola-Hess, J. L. Schultze, and J. Wolf
Inhibition of Nuclear Translocation of Nuclear Factor-{kappa}B Despite Lack of Functional I{kappa}B{alpha} Protein Overcomes Multiple Defects in Apoptosis Signaling in Human B-Cell Malignancies
Clin. Cancer Res., November 15, 2005; 11(22): 8186 - 8194.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Stuhmer, M. Chatterjee, M. Hildebrandt, P. Herrmann, H. Gollasch, C. Gerecke, S. Theurich, L. Cigliano, R. A. Manz, P. T. Daniel, et al.
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Blood, November 15, 2005; 106(10): 3609 - 3617.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al.
Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations
J. Clin. Oncol., October 10, 2005; 23(29): 7296 - 7306.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. C. Anderson, R. Pazdur, and A. T. Farrell
Development of Effective New Treatments for Multiple Myeloma
J. Clin. Oncol., October 1, 2005; 23(28): 7207 - 7211.
[Full Text] [PDF]

Home page
 BloodHome page
N. Giuliani, S. Colla, F. Morandi, M. Lazzaretti, R. Sala, S. Bonomini, M. Grano, S. Colucci, M. Svaldi, and V. Rizzoli
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
Blood, October 1, 2005; 106(7): 2472 - 2483.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. K. Stewart and R. Fonseca
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Yasui, T. Hideshima, N. Raje, A. M. Roccaro, N. Shiraishi, S. Kumar, M. Hamasaki, K. Ishitsuka, Y.-T. Tai, K. Podar, et al.
FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance
Cancer Res., August 15, 2005; 65(16): 7478 - 7484.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Blood, August 1, 2005; 106(3): 1021 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Raje, S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. Munshi, S. R. Green, et al.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Blood, August 1, 2005; 106(3): 1042 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al.
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
Blood, July 15, 2005; 106(2): 706 - 712.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Goker-Alpan and E. Sidransky
Risky business: Gaucher disease and multiple myeloma
Blood, June 15, 2005; 105(12): 4546 - 4547.
[Full Text] [PDF]

Home page
 BloodHome page
M. Ladetto, S. Vallet, A. Trojan, M. Dell'Aquila, L. Monitillo, R. Rosato, L. Santo, D. Drandi, A. Bertola, P. Falco, et al.
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
Blood, June 15, 2005; 105(12): 4784 - 4791.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al.
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
Blood, June 1, 2005; 105(11): 4470 - 4476.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Carvajal-Vergara, S. Tabera, J. C. Montero, A. Esparis-Ogando, R. Lopez-Perez, G. Mateo, N. Gutierrez, M. Parmo-Cabanas, J. Teixido, J. F. San Miguel, et al.
Multifunctional role of Erk5 in multiple myeloma
Blood, June 1, 2005; 105(11): 4492 - 4499.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Ito, T. Nakazato, M. J. Xian, T. Yamada, N. Hozumi, A. Murakami, H. Ohigashi, Y. Ikeda, and M. Kizaki
1'-Acetoxychavicol Acetate Is a Novel Nuclear Factor {kappa}B Inhibitor with Significant Activity against Multiple Myeloma In vitro and In vivo
Cancer Res., May 15, 2005; 65(10): 4417 - 4424.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F.-J. Li, N. Tsuyama, H. Ishikawa, M. Obata, S. Abroun, S. Liu, K.-i. Otsuyama, X. Zheng, Z. Ma, Y. Maki, et al.
A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma
Blood, April 15, 2005; 105(8): 3295 - 3302.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Guedez, A. Martinez, S. Zhao, A. Vivero, S. Pittaluga, M. Stetler-Stevenson, M. Raffeld, and W. G. Stetler-Stevenson
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors
Blood, February 15, 2005; 105(4): 1660 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Jernberg-Wiklund and K. Nilsson
Toward a rational combinaTORial therapy for multiple myeloma
Blood, December 15, 2004; 104(13): 3845 - 3846.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-01-0037v1
104/3/607    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hideshima, T.
Right arrow Articles by Anderson, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hideshima, T.
Right arrow Articles by Anderson, K. C.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Right arrow Cell Cycle
Right arrow Cell Adhesion and Motility
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrow Gene Expression
Right arrow Reviews in Translational Hematology
Right arrow Free Research Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020